Navigation Links
Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
Date:1/13/2009

MINNEAPOLIS, Jan. 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) highlighted results from a clinical study of Macroplastique for the treatment of female stress urinary incontinence, now available in the January 2009 Journal of Urology. This is the first, large, multicenter randomized trial comparing the safety and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique group, the dry/cure rate was 36.9% versus 24.8% in the control group, with a 61.5% improvement compared to 48%, respectively. The authors conclude Macroplastique is a safe, effective, minimally invasive material that can be administered on an outpatient basis.

"This study shows the clear benefits of Macroplastique, an injectable soft tissue urethral bulking agent, bringing the majority of treated patients either freedom from unwanted urinary leakage or fewer episodes," said Uroplasty Chief Executive Officer and President David Kaysen. "Some other commercially available bulking agents may be absorbed into the body, potentially diminishing their clinical benefit. Macroplastique implants are suspended in a water-soluble gel that, once removed from the body, leaves behind the soft, flexible permanent elastomer implants that can sustain the treatment's benefits and provide patients with an improved outcome."

Macroplastique has been available to treat this condition worldwide since 1991. The majority of women treated with Macroplastique report a cure or improvement in their symptoms, with many seeing that improvement as soon as they leave the doctor's office, hospital or clinic.

The study, titled "Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: Results of a multicenter, randomized, controlled, single-blind study," followed 122 Macroplastique p
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
2. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
6. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
7. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
8. August 2008 Mayo Clinic Womens HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
9. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Array BioPharma Inc. (Nasdaq: ... its Chief Executive Officer, Ron Squarer ... conferences.  The public is welcome to participate ... Array BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray ...  Eastern Time Location: Palace Hotel, New York ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... GRONINGEN, Netherlands , July 26 ... organization providing testing services to support preclinical and clinical ... of Xendo Drug Development BV (XDD), headquartered in Groningen, ... organization (CRO), will be known as QPS Netherlands BV ...
... Harco Metal Products (Harco), an industry leader in tube ... contract to manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products ... risk and cost associated with staff injuries caused by physically lifting ...
Cached Medicine Technology:QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... November 27, 2014 “Wekho” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared ... of people. , An interesting new way to travel and ... Android devices. It’s called Wekho and it’s a free ...
(Date:11/27/2014)... Aliso Viejo, California (PRWEB) November 27, 2014 ... have announced a new plugin entitled ProPip, taking FCPX to ... picture in picture effect with a few clicks of a ... is a time saver that our users will appreciate.” , ... with full customization leaving the possibilities truly endless. ProPip is ...
(Date:11/27/2014)... November 27, 2014 This is ... Global Insulin industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... Insulin industry covers information on policy, plans ... cost structure and much more. , ...
(Date:11/27/2014)... 27, 2014 Aria Health President ... employees, prepared and donated 200 Thanksgiving dinners on ... House , a non-profit, community-based organization committed to ... Philadelphia. The dinners were assembled in the dining ... and distributed to vulnerable low income seniors in ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... the Doubletree Hotel in Oak Brook ... 23 The Perinatal Nursing Advisory Council and the March of ... lactation consultants, and the community to the March of Dimes ... Oak Brook, Illinois. All healthcare professionals caring for moms ...
... retinoid tretinoin not the culprit , , FRIDAY, Jan. 23 (HealthDay ... that was tried as a possible skin cancer preventative in ... of several veterans participating in that research. , The ... risk of death was seen in those using retinoid tretinoin ...
... contradicts belief that death rate associated with condition has ... death rate for patients with acute respiratory distress syndrome ... that contradicts the common belief there,s been a steady ... , The researchers reviewed studies conducted between 1984 and ...
... inflammatory bowel disease have higher concentrations of folate in their blood than ... the University of California, San Francisco and UC Berkeley. The findings bring ... to folate - also known as folic acid - deficiency. , ... ...
... Ohio, Jan. 23 Patricia A. Furlong, Founding ... (PPMD), the largest non-profit organization in the United ... muscular dystrophy (Duchenne), announced the one year anniversary ... resources and needs of the Duchenne and Becker ...
... 23 Heartland Information Services,( www.heartlandis.com ), headquartered ... outsourced transcription companies in a report released in ... firm,( www.KLASresearch.com ). In their report, Top 20 ... 2008, Heartland moved up for the third year ...
Cached Medicine News:Health News:March of Dimes 34th Annual Perinatal Conference For Nurses, Health Educators, Social Workers and Other Healthcare Pros Caring for Moms and Babies 2Health News:Acne Cream Not Linked to Raised Death Risk 2Health News:Acne Cream Not Linked to Raised Death Risk 3Health News:Acute Respiratory Distress Syndrome as Deadly as Ever 2Health News:Children with Inflammatory Bowel Disease Have Surprisingly High Folate Levels, Study Finds 2Health News:Children with Inflammatory Bowel Disease Have Surprisingly High Folate Levels, Study Finds 3Health News:Children with Inflammatory Bowel Disease Have Surprisingly High Folate Levels, Study Finds 4Health News:DuchenneConnect Celebrates One Year Anniversary 2Health News:DuchenneConnect Celebrates One Year Anniversary 3Health News:DuchenneConnect Celebrates One Year Anniversary 4Health News:Heartland Information Services Moves Up to 2nd Place in National Survey for Outsourced Transcription 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: